<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146701</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1093N-MA</org_study_id>
    <nct_id>NCT04146701</nct_id>
  </id_info>
  <brief_title>Metabolomics and Microbiomics in Cardiovascular Diseases</brief_title>
  <acronym>MEMORIA</acronym>
  <official_title>Metabolomics and Microbiomics in Cardiovascular Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;MEtabolomics and MicrObiomics in caRdIovAscular diseases Mannheim (MEMORIAM) &quot; is a&#xD;
      single-center, prospective and observational study investigating to identify disease-specific&#xD;
      metabolic, respectively microbiomic, patterns of patients with high-risk cardiovascular&#xD;
      diseases. High-risk cardiovascular diseases comprise patients suffering from acute heart&#xD;
      failure (AHF), ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation&#xD;
      myocardial infarction (NSTEMI), sepsis, septic shock, ischemic and non-ischemic&#xD;
      cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific evidence about the metabolomic and microbiomic changes in high-risk cardiovascular&#xD;
      patients is still lacking.&#xD;
&#xD;
      The acute, critical or progressive disease status predestinies to relevant changes in&#xD;
      cardiovascular metobolism. High-risk patients in the present trial comprise those with acute&#xD;
      heart failure, myocardial infarction (STEMI and NSTEMI), sepsis, septic shock, ischemic and&#xD;
      non-ischemic cardiomyopathy with severely reduced left ventricular ejection fraction (LVEF&#xD;
      &lt;35%).&#xD;
&#xD;
      Therfore this study investigates to identify disease-specific patterns of metabolic and&#xD;
      microbiomic changes. These patterns may help to understand pathophysiology at the metabolic&#xD;
      stages and find out those patients being at highest risk of adverse future outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Disease-specific metabolic/microbiomic biomarker patterns.</measure>
    <time_frame>Within 24h after disease onset</time_frame>
    <description>Expression of disease-specific metabolic/microbiomic biomarker patterns at the time of acute disease presentation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause and cardiovascular mortality.</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>All-cause and cardiovascular mortality, at 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac rehospitalization.</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Cardiac rehospitalization, at 6 months and 12 months.</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Acute Heart Failure</condition>
  <condition>NSTEMI - Non-ST Segment Elevation MI</condition>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Myocardial Infarction, Acute</condition>
  <condition>Sepsis</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Dilated Cardiomyopathy</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Acute heart failure</arm_group_label>
    <description>All consecutive patients admitted with acute heart failure to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STEMI</arm_group_label>
    <description>All consecutive patients admitted with STEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSTEMI</arm_group_label>
    <description>All consecutive patients admitted with NSTEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemic cardiomyopathy</arm_group_label>
    <description>All consecutive patients with an implantable cardioverter defibrillator (ICD) due to ischemic cardiomyopathy and LVEF &lt;35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ischemic cardiomyopathy</arm_group_label>
    <description>All consecutive patients with an implantable cardioverter defibrillator (ICD) due to non-ischemic cardiomyopathy and LVEF &lt;35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepsis</arm_group_label>
    <description>All consecutive patients admitted with sepsis or septic shock to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Clinically inapparent group as controls. One venous blood withdraw will be performed. Demographic and clinical data will be documented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>venous blood withdraw (ca. 40ml)</description>
    <arm_group_label>Acute heart failure</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Ischemic cardiomyopathy</arm_group_label>
    <arm_group_label>NSTEMI</arm_group_label>
    <arm_group_label>Non-ischemic cardiomyopathy</arm_group_label>
    <arm_group_label>STEMI</arm_group_label>
    <arm_group_label>Sepsis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Withdrawl of peripheral venous blood (ca. 40ml) in EDTA, and ammonium heparin serum tubes at&#xD;
      the time of acute disease status.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from acute cardiovascular diseases such as acute heart failure, STEMI,&#xD;
        NSTEMI, ischemic and dilative cardiomyopathies and sepsis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  above mentioned diseases, diagnosis according to respective guideline&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  under 18 years&#xD;
&#xD;
          -  cancer&#xD;
&#xD;
          -  rheumatic diseases&#xD;
&#xD;
          -  infections (except septic group)&#xD;
&#xD;
          -  higher grade heart valve diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Behnes, PD Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Behnes, PD Dr.</last_name>
    <phone>0049 621 383 6239</phone>
    <email>michael.behnes@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ibrahim Akin, Prof. Dr.</last_name>
    <phone>0049 621 383 5229</phone>
    <email>ibrahim.akin@umm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akin Ibrahim, Prof. Dr.</last_name>
      <phone>0049 621 383 5229</phone>
      <email>ibrahim.akin@umm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Michael Behnes</investigator_full_name>
    <investigator_title>Attending physician, adjunct professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

